

26 Oct 2020 |

# Quick Listen: Scrip's Five Must-Know Things

by **Ian Haydock**

Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by *Scrip's* global team.

Take a brief audio tour around *Scrip's* Five Must-Know Things, this time for the business week ended 23 October 2020.

In this edition, we take a look at generic impact on one firm's sales outlook, a major legal settlement in the US, a potential European product approval, corporate performance in India, and mixed results at two big multinationals.

[Click here to explore this interactive content online](#) ✎

These and other Informa Pharma Intelligence podcasts are available on SoundCloud, Apple Podcasts and TuneIn and also via any Alexa-enabled smart speaker or the Alexa app. Just say "Alexa - ask Informa Pharma Intelligence to find podcasts."

Stories mentioned in this episode:

(Also see "[Tecfidera Headwinds Could Mean Cuts At Biogen, Unless Aducanumab Succeeds](#)" - Scrip, 21 Oct, 2020.)

(Also see "[Purdue's \\$8.3bn Settlement With DOJ Requires Reconstitution As Public Benefit Company](#)" - Scrip, 21 Oct, 2020.)

(Also see "[\*Novartis' Cholesterol Drug Inclisiran Closes In On EU Approval\*](#)" - Scrip, 16 Oct, 2020.)

(Also see "[\*India Q2 Preview: Glenmark, Cipla Emerge Stronger\*](#)" - Scrip, 20 Oct, 2020.)

(Also see "[\*Stockwatch: Pandemic And Biosimilar Effects Subordinate Early Third-Quarter Earnings Results\*](#)" - Scrip, 20 Oct, 2020.)